Cargando…
STAT5 fits the RISK profile for cardioprotection
How wonderful would it be if there were a simple, cheap, safe, non-invasive treatment that could be administered to a patient to protect their organs from ischemia and reperfusion? Such a treatment might be used to protect the organs during temporary loss of blood flow, as occurs for example during...
Autores principales: | Davidson, Sean M., Yellon, Derek M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670296/ https://www.ncbi.nlm.nih.gov/pubmed/24058753 http://dx.doi.org/10.4161/jkst.20072 |
Ejemplares similares
-
Exosomes and cardioprotection – A critical analysis
por: Davidson, Sean M., et al.
Publicado: (2018) -
The RISK pathway leading to mitochondria and cardioprotection: how everything started
por: Yellon, Derek M., et al.
Publicado: (2023) -
The importance of clinically relevant background therapy in cardioprotective studies
por: He, Zhenhe, et al.
Publicado: (2020) -
The GTN patch: a simple and effective new approach to cardioprotection?
por: Yellon, Derek M., et al.
Publicado: (2018) -
The novel adipocytokine visfatin exerts direct cardioprotective effects
por: Lim, Shiang Y, et al.
Publicado: (2008)